- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03395080
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma (P204)
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Study Overview
Status
Intervention / Treatment
Detailed Description
This study employs a "basket" design to concurrently investigate DKN-01 as monotherapy and in combination with paclitaxel in patients with recurrent epithelial endometrial cancer (EEC), epithelial ovarian cancer (EOC), or carcinosarcoma (malignant mixed Mullerian tumor [MMMT]. Thus, 6 distinct patient groups are being independently investigated:
- 300mg DKN-01 monotherapy in recurrent EEC (Group 1)
- 300mg DKN-01+paclitaxel in recurrent EEC (Group 2)
- 300mg DKN-01 monotherapy in recurrent EOC (Group 3)
- 300mg DKN-01+paclitaxel in recurrent EOC (Group 4)
- 600mg DKN-01 monotherapy in recurrent carcinosarcoma (MMMT) (Group 5)
- 600mg DKN-01+paclitaxel in recurrent carcinosarcoma (MMMT) (Group 6)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth
-
-
Florida
-
West Palm Beach, Florida, United States, 33401
- Florida Cancer Specialists & Research Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- HCA Midwest Health System Clinical Research
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Hilliard, Ohio, United States, 43026
- Ohio State University Wexner Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Stephenson Cancer Center - University of Oklahoma Health Sciences Center
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- The University of Tennessee West Cancer Center
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53715
- University of Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert and Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Diagnosis:
- Epithelial Endometrial Cancer: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent previously treated EEC.
- Epithelial Ovarian Cancer: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent platinum-resistant/refractory EOC, primary peritoneal, or fallopian tube cancer (i.e., disease recurrence within 6 months of completion of or progression during platinum-based chemotherapy).
- Carcinosarcoma/Malignant Mixed Mullerian Tumors: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent uterine or ovarian carcinosarcoma (MMMT). Patients must have had only 1 prior chemotherapeutic regimen for management of carcinosarcoma that may have been included chemotherapy (including in adjuvant setting), chemotherapy and radiotherapy, and/or consolidation/maintenance therapy.
Refractory or intolerant to at least one prior standard therapy(ies) for metastatic or locally advanced disease (see Inclusion Criterion #1c for Groups 5-6).
- If prior therapy consisted of palliative chemoradiation therapy, it will be considered one line of therapy.
- Prior treatment with paclitaxel as part of definitive therapy regimen is acceptable, provided the patient is not intolerant of paclitaxel.
- Patients who are not eligible to receive paclitaxel will be allowed to receive single agent DKN-01.
- Tumor tissue for mandatory pre-treatment and on-treatment biopsies.
- One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.
- Ambulatory and ≥18 years of age.
ECOG performance status (PS) of 0 or 1
a. ECOG PS of 2 may be eligible upon the review and approval of the Medical Monitor.
- Estimated life expectancy of at least 3 months, in the judgment of the Investigator.
- Disease-free of active second/secondary or prior malignancies for ≥2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.
- Acceptable liver, renal, hematologic and coagulation function
- Females of child bearing potential and male partners of female patients must agree to use adequate contraception during the study and for 6 months after their last dose of study drug.
- Reliable and willing to make themselves available for the duration of the study and are willing to follow study-specific procedures.
- Provided written informed consent prior to any study-specific procedures.
Exclusion Criteria:
- Patients with the following pure histologies of endometrial or ovarian cancer are not eligible for enrollment: germ cell, sex cord stroma, or sarcoma.
- New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia.
- Fridericia-corrected QT interval (QTcF) > 470 msec (female) or history of congenital long QT syndrome.
- Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.
- Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb), unless hepatitis C virus ribonucleic acid (HCV RNA) undetected/negative.
- History of major organ transplant (i.e., heart, lungs, liver, or kidney).
- History of autologous/allogenic bone marrow transplant.
- Serious nonmalignant disease
- Pregnant or nursing.
- History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant.
- Symptomatic central nervous system (CNS) malignancy or metastasis.
- Known osteoblastic bony metastasis
- Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days for nitrosoureas or mitomycin C)
- Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to study entry.
- Clinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01
- History of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these hypersensitivities will be eligible to receive single agent DKN-01
- Prior radiation therapy within 14 days prior to study entry
- Currently receiving any other investigational agent or received an investigational agent within last 30 days of study entry.
- Previously treated with an anti-DKK1 therapy
- Significant allergy to a pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient
- Active substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DKN-01 monotherapy in recurrent EEC
300mg DKN-01 monotherapy in recurrent EEC
|
Administered by IV infusion
|
Experimental: DKN-01+paclitaxel in recurrent EEC
300mg DKN-01+paclitaxel in recurrent EEC
|
Administered by IV infusion
Administered by IV infusion
Other Names:
|
Experimental: DKN-01 monotherapy in recurrent EOC
300mg DKN-01 monotherapy in recurrent EOC
|
Administered by IV infusion
|
Experimental: DKN-01+paclitaxel in recurrent EOC
300mg DKN-01+paclitaxel in recurrent EOC
|
Administered by IV infusion
Administered by IV infusion
Other Names:
|
Experimental: DKN-01 monotherapy in carcinosarcoma
600mg DKN-01 monotherapy in carcinosarcoma
|
Administered by IV infusion
|
Experimental: DKN-01 +paclitaxel in carcinosarcoma
600mg DKN-01 +paclitaxel in carcinosarcoma
|
Administered by IV infusion
Other Names:
Administered by IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Objective Response Rate (ORR) in EEC or EOC Patients
Time Frame: Baseline to study completion (approximately 6 months)
|
Best overall response of Complete Response (CR; disappearance of all target lesions, any pathological lymph nodes whether target or non-target must have reduction in short axis to <10mm) or Partial Response (PR; at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1)
|
Baseline to study completion (approximately 6 months)
|
Number of Subjects With Objective Response Rate (ORR) in Carcinosarcoma (MMMT) Patients
Time Frame: Baseline to study completion (approximately 6 months)
|
Best overall response of Complete Response (CR; disappearance of all target lesions, any pathological lymph nodes whether target or non-target must have reduction in short axis to <10mm) or Partial Response (PR; at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1)
|
Baseline to study completion (approximately 6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Objective Disease Control Rate (ODCR) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (approximately 6 months)
|
Objective Disease Control Rate (ODCR) was defined as the percentage of subjects with a Best Overall Response of Complete Response (CR; disappearance of all target lesions, any pathological lymph nodes whether target or non-target must have reduction in short axis to <10mm), Partial Response (PR; at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters), or Stable Disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as Progressive Disease) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1)
|
Baseline to study completion (approximately 6 months)
|
Overall Survival (OS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (maximum 17.6 months)
|
Overall Survival (OS) is defined as the time from first dose of study drug until date of death due to any cause.
|
Baseline to study completion (maximum 17.6 months)
|
Progression-free Survival (PFS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (maximum 7.1 months)
|
Progression-free survival (PFS) is defined as time from first dose of study drug to first documentation of PD (per RECIST 1.1) or death due to any cause.
|
Baseline to study completion (maximum 7.1 months)
|
Duration of Response (DoR) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (approximately 11 months)
|
Duration of Response (DoR) includes only patients that have responded with an objective disease response (PR or CR) and is defined as the time from the first tumor assessment that supports the patient's objective disease response to the time of PD or death due to any cause.
|
Baseline to study completion (approximately 11 months)
|
Duration of Complete Response (DoCR) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (approximately 11 months)
|
Number of participants analyzed only includes patients with a CR and is otherwise defined and analyzed similar to DoR.
|
Baseline to study completion (approximately 11 months)
|
Duration of Clinical Benefit (DoCB) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (approximately 13.1 months)
|
Duration of Clinical Benefit (DoCB) includes patients with a Best Overall Response of CR, PR, or SD and is defined as the time from the first tumor assessment of CR, PR or SD to the time of PD or death due to any cause.
|
Baseline to study completion (approximately 13.1 months)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Curve (AUC)
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Number of Subjects With Response to Therapy in Patients With and Without Activating β-catenin Mutations and/or Wnt Signaling Genetic Alterations in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT)
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Dickkopf-1 (DKK1) Concentration in Serum and Plasma Relative to Safety and Efficacy Outcomes in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Number of Subjects With Adverse Drug Reactions and Toxicities as Evaluated by NCI CTCAE v5.0 of DKN-01 600 mg +/- Paclitaxel in Patients With Recurrent Carcinosarcoma (MMMT) in Carcinosarcoma (MMMT) Patients
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Maximum Plasma Concentration (Cmax)
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Time Taken to Reach the Maximum Plasma Concentration (Tmax)
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Number of Subjects With Adverse Drug Reactions and Toxicities as Evaluated by NCI CTCAE v4.03 as DKN-01 as Monotherapy or in Combination With Paclitaxel in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT)
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Number of Subjects With Adverse Drug Reactions and Toxicities to Study Treatment Regimen in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT) as Evaluated by NCI CTCAE v5.0
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Concentration of DKN-01 Antibodies in Human Serum in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT)
Time Frame: Baseline to study completion (approximately 6 months)
|
Baseline to study completion (approximately 6 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cynthia Sirard, MD, Leap Therapeutics
- Principal Investigator: Rebecca Arend, MD, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Neoplasms, Complex and Mixed
- Sarcoma
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Endometrial Neoplasms
- Carcinosarcoma
- Mixed Tumor, Mullerian
- Carcinoma, Ovarian Epithelial
- Uterine Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- DEK-DKK1-P204
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on 300mg DKN-01
-
Leap Therapeutics, Inc.AvailableGastric Cancer | Ovarian Cancer | Gastric Adenocarcinoma | Carcinosarcoma | Endometrial Cancer | Adenocarcinoma of the Gastroesophageal Junction | GastroEsophageal Cancer | Uterine Cancer | Esophageal Neoplasm | Squamous Cell CarcinomaUnited States
-
Leap Therapeutics, Inc.CompletedMultiple Myeloma | Non-Small Cell Lung Cancer | Solid TumorsUnited States
-
Johannes Gutenberg University MainzLeap Therapeutics, Inc.Unknown
-
Leap Therapeutics, Inc.BeiGeneActive, not recruitingGastric Cancer | Gastric Adenocarcinoma | GastroEsophageal CancerUnited States, Korea, Republic of, Germany
-
Leap Therapeutics, Inc.Merck Sharp & Dohme LLCCompletedEsophageal Neoplasms | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma | Gastroesophageal CancerUnited States
-
NYU Langone HealthLeap Therapeutics, Inc.Terminated
-
Royal Marsden NHS Foundation TrustRecruitingMetastatic Gastric Cancer | Metastatic Esophageal CancerUnited Kingdom
-
Maxinovel Pty., Ltd.Not yet recruitingAdvanced / Metastatic Solid Tumors
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Leap Therapeutics,...Recruiting
-
Massachusetts General HospitalBristol-Myers Squibb; Leap Therapeutics, Inc.TerminatedBiliary Tract CancerUnited States